NVSEF News and Press, Novartis Ag Basel Akt From 02/04/22

The following slide deck was published by Novartis AG in conjunction with their 2021 Q4 earnings call. For further details see: Novartis AG 2021 Q4 - Results - Earnings Call Presentation

Fisher’s 13F portfolio value increased from ~$161B to ~$179B in Q4 2021. Amazon, Netflix, Meta Platforms, and PayPal Holdings were increased while reducing Visa, Cisco Systems, Walt Disney, Intel, Wal-Mart, UnitedHealth, and Starbucks this quarter. The top three positions a...

Contrarian idea after the Q4 results. Solid Q4 results. Positive outlook, we rate Novartis as a Buy. For further details see: Novartis: A Good Long-Term Pick

Novartis AG (NVS) Q4 2021 Earnings Conference Call February 02, 2022, 08:00 ET Company Participants Samir Shah - Global Head, IR Vasant Narasimhan - CEO Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne Schaffert - President, Novartis Oncology Harry Kirsch - CFO Richard Sayn...

Novartis is a large cap pharma company from Switzerland with a portfolio that is broadly diversified both in terms of products and in terms of geography. Its three top-selling drugs account for only 17% of 2020 net sales, and Novartis typically generates less than 40% of total sales i...

The year 2021, was relatively mixed for biotech stocks with some posting significant gains while others pulled back dramatically. However, moving into 2022, we could see a significant rebound based on products launched in 2021, or in anticipation of new product announcements. Sage T...

Pharma/biotech is the most attractive subsector. The most overvalued one is life science tools. IXJ: an alternative to XLV. 10 stocks cheaper than their peers in December. For further details see: IXJ: Healthcare Dashboard For December

Kiplinger "insights for investors" online, first-published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth compiled 7/1/21. 40 European “Dividend Aristocrats,” showed 10 years of stable or inc...

The following slide deck was published by Novartis AG in conjunction with this event. For further details see: Novartis (NVS) R&D Day - Slideshow

FDEU was the 2nd-ranked DxY fund in our recent Quality CEF report. FDEU achieves full distribution coverage through investment into high dividend stocks. However, value and options strategy has caused underperformance vs. benchmark. Wide discount provides an attractive entry p...